AbbVie’s (ABBV) treatment of neuroendocrine carcinoma was granted FDA orphan designation, according to a post on the agency’s website.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie reports ‘positive’ results from Phase 3 AFFIRM study of Skyrizi
- Uber, Verizon, AbbVie, IBM and McDonald’s Insider Shake-Up
- AbbVie’s SKYRIZI Lactation Study Completion Adds Quiet Support to Its IBD Growth Story
- AbbVie’s XEN45 Glaucoma Study Signals New Angle in Eye Care Strategy
- AbbVie’s Upadacitinib Study in Teens With Eczema: Fresh Real‑World Data Investors Should Watch